From: Stereotactic body radiation therapy for abdominal oligometastases: a biological and clinical review
Patients (N) | Primary cancer | Dose (Gy) × fr | Median follow up (mos) | Outcomes | |
---|---|---|---|---|---|
Jereczek-Fossa et al. 2009 [53] | 14 | Prostate | 33 (mean) × 3-5 | Mean 18.6 | - No in-field clinical progression |
- Distant or regional LN progression at mean time of 12.7 mo | |||||
- All patients with relapse had high-risk disease | |||||
Bignardi et al. 2011 [54] | 19 | CRC (5/19) | 45 × 6 | 12 | Actuarial rate of freedom from local progression: 77.8 ± 13.9 at both 12 and 24 mos |
Minimal acute and chronic toxicity | |||||
Choi et al. 2010 [55] | 30 | Uterus and cervix | EBRT: 27–45 (n = 4 pts) | 15 | 4-year LC rate: 67.4% |
SBRT: 33–45 × 3 (n = 24 pts) | 4-year OS rate: 50.1% | ||||
(all 30 pts). | |||||
Kim et al. 2009 [56] | 7 | Gastric (salvage aftersurgery) | 48 (median) × 3 | 26 | Complete response: n = 5 |
Partial response: n = 2 | |||||
Kim et al. 2009 [57] | 7 | CRC | Escalated dose 36–51 × 3 | 26 | Median survival: 37 mos |
1-year OS: 100% | |||||
3-year OS: 71.4% | |||||
G4: intestinal obstruction in 1/7 patients | |||||
Bae et al. 2012 [51] | 41 | CRC | 48(45 – 60) × 3 | 28 | -PFS, LC and OS rates |
3-year rates : 40%, 64%, 60% | |||||
5-year rates : 40, 57%, 38% | |||||
-G3 perforation after pelvic LN SBRT;G4 obstruction of para-aortic LN SBRT |